Urofollitropin
drugOn this page
Also known as BravelleFertinexFertinormFollitropin humanFostimonGonadotraphon fshMetrodin high purityOrgafolUrofolitropinaUrofollitrophinUrofollitropine
Summary
Urofollitropin (CHEMBL1201520) is an approved unknown (ATC G03GA04) targeting FSHR; indicated across 5 conditions including infertility disorder and spermatogenic failure.
At a glance
- Status: Approved (max clinical phase 4)
- Modality: Unknown
- ATC class: G03GA04
- Targets: 1 (FSHR)
- Indications: 5 conditions
- Clinical trials: 10
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL1201520 |
| Name | Urofollitropin |
| Type | Unknown |
| Max phase | 4 |
| ATC | G03GA04 |
Also known as: Bravelle, Fertinex, Fertinorm, Follitropin human, Fostimon, Gonadotraphon fsh, Metrodin high purity, Orgafol, Urofolitropina, Urofollitrophin, Urofollitropin, Urofollitropine
Targets
Targets
Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).
| Gene | Target | Action | pAffinity | Cancer dependency | UniProt |
|---|---|---|---|---|---|
| FSHR | FSH receptor | Agonist | 0% | P23945 |
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
Aggregated over 1 target gene(s): FSHR.
Top Reactome pathways
2 total, by targets touching each:
| Pathway | Targets | Genes |
|---|---|---|
| Hormone ligand-binding receptors | 1 | FSHR |
| G alpha (s) signalling events | 1 | FSHR |
Dominant GO biological processes
| GO term | Targets |
|---|---|
| primary ovarian follicle growth | 1 |
| regulation of systemic arterial blood pressure | 1 |
| G protein-coupled receptor signaling pathway | 1 |
| adenylate cyclase-activating G protein-coupled receptor signaling pathway | 1 |
| adenylate cyclase-inhibiting G protein-coupled receptor signaling pathway | 1 |
| phospholipase C-activating G protein-coupled receptor signaling pathway | 1 |
| spermatogenesis | 1 |
| female gamete generation | 1 |
| locomotory behavior | 1 |
| gonad development | 1 |
| male gonad development | 1 |
| female gonad development | 1 |
| hormone-mediated signaling pathway | 1 |
| intracellular water homeostasis | 1 |
| regulation of platelet-derived growth factor receptor signaling pathway | 1 |
Indications & clinical
Indications
5 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| infertility disorder | 3 | MONDO:0005047 | EFO:0000545 |
| spermatogenic failure | 3 | MONDO:0004983 | EFO:0000279 |
| male infertility | 3 | MONDO:0005372 | EFO:0004248 |
| anovulation | 3 | MONDO:0002775 | MONDO:0002775 |
| female infertility | 1 | MONDO:0021124 | EFO:0008560 |
Clinical trials
Total trials: 10.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE3 | 3 |
| Not specified | 3 |
| PHASE4 | 2 |
| PHASE2 | 1 |
| PHASE1 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT01417195 | PHASE4 | COMPLETED | Menopur Mixed Protocol |
| NCT01969201 | PHASE4 | COMPLETED | FSH in GnRH-AntagoniST Controlled Ovarian Hyperstimulation Cycles (FAST) |
| NCT00971152 | PHASE3 | COMPLETED | Effect of a Higher Than Maximum 450IU Gonadotropin Dose in an In-vitro Fertilization Cycle |
| NCT02275169 | PHASE3 | UNKNOWN | FSH Treatment for Non-obstructive Azoospermic Patients |
| NCT02605070 | PHASE3 | TERMINATED | Pilot Study on the Effects of FSH Treatment on the Epigenetic Characteristics of Spermatozoa in Infertile Patients With Severe Oligozoospermia |
| NCT01337531 | PHASE2 | UNKNOWN | Recombinant Versus Highly Purified FSH in Polycystic Ovary Syndrome (PCOS) |
| NCT01354886 | PHASE1 | COMPLETED | Single Dose FSH-GEX™ in Healthy Volunteers |
| NCT00677573 | Not specified | UNKNOWN | Efficacy of Urinary Follicle-Stimulating Hormone (FSH) Among Poor Responders |
| NCT01669291 | Not specified | COMPLETED | Effect of GnRH Antagonist vs Agonist Long on IVF Outcome, Peak Estradiol Level,and Duration of Stimulation |
| NCT01882166 | Not specified | TERMINATED | Time-lapse Monitoring of Early Embryo Development After Ovarian Stimulation During Infertility Treatment |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.
1 molecules share ≥1 primary target. Top 1 by shared-target count:
| Molecule | Source | Status | Shared targets |
|---|---|---|---|
| Yohimbine | PubChem | Approved | FSHR |
Related Atlas pages
- Genes: FSHR
- Diseases: infertility disorder, spermatogenic failure, male infertility, anovulation
- Drugs: Yohimbine